Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report

被引：0
|
作者：
F. Guisier
N. Piton
M. Bellefleur
N. Delberghe
G. Avenel
E. Angot
O. Vittecoq
M. Ould-Slimane
H. Morisse-Pradier
M. Salaun
L. Thiberville
机构：
[1] CHU Charles Nicolle,Service de pneumologie, oncologie thoracique et soins intensifs respiratoires
[2] LITIS QuantIF EA4108,INSERM CIC 1404
[3] Normadie Univ,Service d’anatomie et cytologie pathologiques
[4] CHU Charles Nicolle,Service de rhumatologie
[5] CHU Charles Nicolle,Service d’orthopédie et traumatologie
[6] CHU Charles Nicolle,undefined
[7] CHU Charles Nicolle,undefined
来源：
BMC Cancer | / 20卷
关键词：
-rearranged NSCLC; ALK inhibitors; Crizotinib; Ceritinib; Drug toxicity; Osteitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
    Guisier, F.
    Piton, N.
    Bellefleur, M.
    Delberghe, N.
    Avenel, G.
    Angot, E.
    Vittecoq, O.
    Ould-Slimane, M.
    Morisse-Pradier, H.
    Salaun, M.
    Thiberville, L.
    [J]. BMC CANCER, 2020, 20 (01)
  • [2] Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient
    Duarte, F.
    Rodrigues, L.
    Paes, F.
    Diniz, P.
    De Almada, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S667 - S667
  • [3] Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
    Duarte, Flavia Amaral
    Rodrigues, Leonardo Brand
    Paes, Flavia Rocha
    Costa Diniz, Paulo Henrique
    Cuba de Almada Lima, Helena Flavia
    [J]. BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [4] Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
    Flávia Amaral Duarte
    Leonardo Brand Rodrigues
    Flávia Rocha Paes
    Paulo Henrique Costa Diniz
    Helena Flávia Cuba de Almada Lima
    [J]. BMC Pulmonary Medicine, 21
  • [5] Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease
    Domenech, Marta
    Jove, Maria
    Aso, Samantha
    Marin, Mar
    Nadal, Ernest
    [J]. LUNG CANCER, 2018, 119 : 99 - 102
  • [6] ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report
    Qiu, Ye
    Li, Bixun
    Zhang, Yihong
    Guo, Xiaoyun
    Xiang, Chunzhi
    Wang, Congshui
    Lu, Yang
    Ren, Shuang
    Zhao, Juan
    [J]. MEDICINE, 2019, 98 (11)
  • [7] Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
    Nagumo, Yoshiyuki
    Maejima, Aiko
    Toyoshima, Yuta
    Komiyama, Motokiyo
    Yonemori, Kan
    Yoshida, Akihiko
    Fujimoto, Hiroyuki
    [J]. INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2018, 48 : 1 - 4
  • [8] Local Treatment for Oligoprogression/ Oligometastases After Failure to Crizotinib for ALK-Rearranged Stage IV Lung Cancer
    Kam, T. Y.
    Li, J.
    Lim, M. Y.
    Chan, O. S. H.
    Cheung, K. C.
    Lee, V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S685 - S685
  • [9] Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient
    Ai, Xinghao
    Niu, Xiaomin
    Chang, Lianpeng
    Chen, Rongrong
    Ou, Sai-Hong Ignatius
    Lu, Shun
    [J]. LUNG CANCER, 2018, 123 : 83 - 86
  • [10] Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib
    Zhu, Viola W.
    Cui, J. Jean
    Fernandez-Rocha, Maria
    Schrock, Alexa B.
    Ali, Siraj M.
    Ou, Sai-Hong Ignatius
    [J]. LUNG CANCER, 2017, 110 : 32 - 34
12345